Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-30 22:04:09 - browse：9

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

hotspot

WSS

Juul documents reveal insider tactics on political lobbying

A single Democrat is willing to weaken Medicare negotiation power

Study gives hint on South Asians’ higher risk of cardiovascular disease

Too many hospitalized Covid

What’s missing from the debate over nursing home staff minimums

Long Covid research funding gets a major boost from NIH

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Sports medicine is finally prioritizing gender equality

Updated Covid vaccine has 54% effectiveness, new study suggests

Medical leaders decry Supreme Court decision on affirmative action

AMAs digital advisors table RPM coding reform proposal, again

Medical leaders decry Supreme Court decision on affirmative action

Adopting new red light myopia treatments may be short

Activists slam private health insurers over coverage restrictions

Ebola vaccine can save some who are already sick, per new study

hotspot

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Problems with a popular proposal to regulate AI in health care

The Biogen Aduhelm mess could happen again

Problems with a popular proposal to regulate AI in health care

Bernie brings in new pharma CEOs to talk drug prices

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

hotspot

explore

hotspot

entertainment